Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 0.99 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 0.99 |
| ▸ | KIT | P10721 | 11/20 | 0.99 |
| ▸ | LDLR | P01130 | 8/20 | 0.99 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.99 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.99 |
| ▸ | LCK | P06239 | 4/20 | 0.99 |
| ▸ | LYN | P07948 | 4/20 | 0.99 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.99 |
| ▸ | FLT3 | P36888 | 4/20 | 0.99 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.99 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.99 |
| ▸ | SRC | P12931 | 2/20 | 0.99 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.99 |
| ▸ | CA12 | O43570 | 1/20 | 0.99 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.99 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.99 |
| ▸ | STK10 | O94804 | 1/20 | 0.99 |
| ▸ | CA1 | P00915 | 1/20 | 0.99 |
| ▸ | CA2 | P00918 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL1565706 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL434496 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1459790 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28656586 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL235245 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL18095566 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL2223849 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1460791 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29392981 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28663798 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731199-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727534-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING BREAST CANCER | Burzynski, Stanislaw R. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250057841-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | HANDA ONCOLOGY, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024263798-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PROSTATE CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263966-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263813-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263960-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263963-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING HEAD AND NECK CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263643-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING BREAST CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263804-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING KIDNEY CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263972-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING UNCOMMON CANCERS | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263801-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING OVARIAN CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| US-12064428-B2 | Kinase inhibitor salts and compositions thereof | HANDA ONCOLOGY, LLC (US) | 2024-08-20 | — | — | US | disclosed |
| CN-118409022-A | Dissolution detection method of nilotinib capsules | 郑州德迈药业有限公司 | 2024-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064428-B2 | Kinase inhibitor salts and compositions thereof | SRC, STK25, STK35 | ABL1 9/4885BCR 630/4885KIT 553/4885 |
| US-20250057841-A1 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | BRAF, MAP3K15, RAF1 | ABL1 448/4885BCR 3530/4885KIT 622/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | ABL1 3535/4885BCR 1256/4885KIT 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.